PHVS 주가 차트
PHVS 주가 예측
Pharvaris NV
$29.79
-0.53%
$-0.16
오늘 기준:May 12, 09:46:44 GMT-4
뒤로
Pharvaris NV (PHVS) 주가 예측
주요 통계
이전 종가
$29.95
시가
$30
일일 범위
$29.52 - $30.02
52주 범위
$14.58 - $31.14
거래량
13.2K
평균 거래량
206.9K
배당수익률
--
EPS(TTM)
-3.00
시가총액
$1.9B
PHVS란 무엇인가요?
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
